Tag Archives: extract

Medicinal Cannabis Does Not Influence the Clinical Pharmacokinetics of Irinotecan and Docetaxel

Posted on by
Reply

“For the past 4,000 years, patients and doctors of each era have resorted to cannabis when conventional treatments were ineffective or lacking. Indeed, in oncology beneficial effects have been reported for cancer-associated anorexia, chemotherapy-induced nausea and vomiting, and palliation…

The only U.S. Food and Drug Administration (FDA)-approved medicinal cannabis products are an oral formulation containing dronabinol (Marinol®)… the synthetic version of delta9-tetrahydrocannabinol (THC), the main pharmacologically active cannabinoid, and capsules containing nabilone, an analog of dronabinol (Cesamet®)…

…many patients claim (subjectively) that a whole or partially purified extract of Cannabis sativa L. offers advantages over a single isolated ingredient…

We anticipated an increased use of medicinal cannabis concurrent with anticancer drugs, and undertook a drug-interaction study to evaluate the effect of concomitant medicinal cannabis on the pharmacokinetics of irinotecan and docetaxel…

Conclusion. Coadministration of medicinal cannabis, as herbal tea, in cancer patients treated with irinotecan or docetaxel does not significantly influence the plasma pharmacokinetics of these drugs. The evaluated variety of medicinal cannabis can be administered concomitantly with both anticancer agents without dose adjustments.”

Full text: http://theoncologist.alphamedpress.org/content/12/3/291.long

Cannabis eases multiple sclerosis (MS) stiffness per study published in neurology journal

Posted on by
Reply

“The trial, led by John Peter Zajicek of Britain’s Clinical Neurology Research Group, says standardized doses of cannabis extract can be useful in easing pain and spasms in this disease.”

Use of cannabis extract helps ease painful muscle stiffness among patients with multiple sclerosis (MS), according to a large new trial.

“Use of cannabis extract helps ease painful muscle stiffness among patients with multiple sclerosis (MS), according to a large trial published on Tuesday in the Journal of Neurology, Neurosurgery and Psychiatry…”

http://www.nydailynews.com/life-style/health/cannabis-eases-multiple-sclerosis-ms-stiffness-study-article-1.1179450

 

A Double-Blind, Placebo-Controlled, Crossover Pilot Trial With Extension Using an Oral Mucosal Cannabinoid Extract for Treatment of Chemotherapy-Induced Neuropathic Pain.

Posted on by
Reply

“Neuropathic pain caused by chemotherapy limits dosing and duration of potentially life-saving anti-cancer treatment and impairs quality of life. Chemotherapeutic neuropathy responds poorly to conventional treatments, and there is an urgent medical need for new treatments. Recent preclinical studies demonstrate that cannabinoid agonists suppress established chemotherapy-evoked neuropathy.

This was a pilot trial to begin to investigate a currently available cannabinoid agent, nabiximols (oral mucosal spray containing cannabinoids), in the treatment of chemotherapy-induced neuropathic pain.

CONCLUSION:

Chemotherapy-induced neuropathic pain is particularly resistant to currently available treatments. This pilot trial found a number needed to treat of five and an average decrease of 2.6 on an 11-point NRS-PI in five “responders” (as compared with a decrease of 0.6 with placebo) and supports that it is worthwhile to study nabiximols in a full randomized, placebo-controlled trial of chemotherapy-induced neuropathic pain.”

http://www.ncbi.nlm.nih.gov/pubmed/23742737

Synthetic and Patented Cannabinoids

Posted on by
Reply

“Historically, laboratory synthesis of cannabinoids were often based on the structure of herbal cannabinoids, and a large number of analogs have been produced and tested, especially in a group led by Roger Adams as early as 1941 and later in a group led by Raphael Mechoulam.

Newer compounds are no longer related to natural cannabinoids or are based on the structure of the endogenous cannabinoids.

Synthetic cannabinoids are particularly useful in experiments to determine the relationship between the structure and activity of cannabinoid compounds, by making systematic, incremental modifications of cannabinoid molecules.

Medications containing natural or synthetic cannabinoids or cannabinoid analogs:

  • Dronabinol (Marinol), is Δ9-tetrahydrocannabinol (THC), used as an appetite stimulant, anti-emetic, and analgesic
  • Nabilone (Cesamet), a synthetic cannabinoid and an analog of Marinol. It is Schedule II unlike Marinol, which is Schedule III
  • Sativex, a cannabinoid extract oral spray containing THC, CBD, and other cannabinoids used for neuropathic pain and spasticity in Canada and Spain. Sativex develops whole-plant cannabinoid medicines
  • Rimonabant (SR141716), a selective cannabinoid (CB1) receptor antagonist used as an anti-obesity drug under the proprietary name Acomplia. It is also used for smoking cessation

Other notable synthetic cannabinoids include:

  • CP-55940, produced in 1974, this synthetic cannabinoid receptor agonist is many times more potent than THC
  • Dimethylheptylpyran
  • HU-210, about 100 times as potent as THC
  • HU-331 a potential anti-cancer drug derived from cannabidiol that specifically inhibits topoisomerase II.
  • SR144528, a CB2 receptor antagonists
  • WIN 55, a potent cannabinoid receptor agonist
  • JWH-133, a potent selective CB2 receptor agonist
  • Levonantradol (Nantrodolum), an anti-emetic and analgesic but not currently in use in medicine”

http://www.news-medical.net/health/Synthetic-and-Patented-Cannabinoids.aspx

Cannabis Science Reports Cancer Tumors Continues to Shrink and Die as Apparent Pieces of the Dying Cancer Tumors Begin to Fall off as Evidenced in Newest Photos of the 3rd Squamous Cell Carcinoma Patient

Posted on by
Reply

“Cannabis Science, Inc. a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is pleased to release new updated photos from the 3rd cancer patient self-administering cannabis extracts. This patient has severe squamous cell carcinoma on their head that was resistant to chemo and radiation therapy, which left the patient with large tumor masses on their head. With these new photo updates you can see the drastic change in appearance of the tumors and how the topical cannabis extract is killing them. 

Cannabis Science has been working very closely with this patient and is continuing to see vast improvement to his treatment resistant squamous cell carcinoma. Prior to using cannabis-based extracts this patient had received radiation and chemotherapy for his condition. This patient notices a huge difference between the treatments and had stated, “While on radiation treatments, each day was stressful and after each treatment I felt horrible as if my entire body was dying organ by organ. While using the Oil, I have noticed that my overall health seems much better. I sleep the recommended hours, unlike the insomnia I suffered while on radiation, and unlike the radiation that caused the restless sleep and nightmares, on the Oil I sleep like a baby.” The patient also mentioned that while showering they would see bits and pieces of the tumor falling off with the water as he was cleaning his head.

This patient is very pleased with the results of the topical cannabis extract so far and said he enjoyed absolutely nothing about radiation and felt constantly sick and just overall unhealthy, but with using the oil he said, “I feel myself being restored, not tortured.””

More: http://www.drugs.com/clinical_trials/cannabis-science-reports-cancer-tumors-continues-shrink-die-apparent-pieces-dying-cancer-tumors-13168.html

Physician’s documentation confirms successful treatment of basal cell carcinoma with topical cannabis extract

Posted on by
Reply

“We are pleased to announce that we have physician’s documentation that confirms the successful treatment of basal cell carcinoma that resulted from the application of a topical cannabis extract.” 

Currently, there is a tremendous amount of controversy with respect to the effects that cannabinoids have on cancers. Endocannabinoids, phytocannabinoids, and synthetic cannabinoids have demonstrated cancer killing and anti-metastatic properties in tissue culture and in animal models.

While formal, proper, FDA approved clinical trials that would prove or disprove the therapeutic potential of cannabis extracts for treating cancers; trials have not been carried out. Nevertheless, a significant number of anecdotal observations have accumulated that suggest people suffering from a variety of cancers appear to have been cured by ingesting what is known as “Rick Simpson’s hemp oil”.”

More: http://www.news-medical.net/news/20110407/Physicians-documentation-confirms-successful-treatment-of-basal-cell-carcinoma-with-topical-cannabis-extract.aspx

The trypanocidal effect of Cannabis sativa constituents in experimental animal trypanosomiasis.

Posted on by
Reply

Image result for cannabis sativa

“The effect of Cannabis sativa on trypanosome-infected rats was examined. An aqueous extract of the seeds administered at a dose of 50 mg/kg/d cured animals infected with Trypanosome brucei brucei of blood stream parasites.

Six fractions eluted from the crude extract by column chromatography were assessed for trypanocidal properties. Of these, only 2 fractions retained trypanocidal activity by curing mice infected with T brucei brucei.”

http://www.ncbi.nlm.nih.gov/pubmed/7900270

Related image

“Trypanosoma brucei is a species of parasitic kinetoplastid belonging to the genus Trypanosoma. The parasite is the cause of a vector-borne disease of vertebrate animals, including humans, carried by genera of tsetse fly in sub-Saharan Africa. In humans T. brucei causes African trypanosomiasis, or sleeping sickness.”  https://en.wikipedia.org/wiki/Trypanosoma_brucei

“A trypanocidal agent is an antiprotozoal agent that acts upon trypanosome parasites.”  https://en.wikipedia.org/wiki/Trypanocidal_agent

Antihyperalgesic effect of a Cannabis sativa extract in a rat model of neuropathic pain: mechanisms involved.

Posted on by
Reply

Abstract

“This study aimed to give a rationale for the employment of phytocannabinoid formulations to treat neuropathic pain. It was found that a controlled cannabis extract, containing multiple cannabinoids, in a defined ratio, and other non-cannabinoid fractions (terpenes and flavonoids) provided better antinociceptive efficacy than the single cannabinoid given alone, when tested in a rat model of neuropathic pain. The results also demonstrated that such an antihyperalgesic effect did not involve the cannabinoid CB1 and CB2 receptors, whereas it was mediated by vanilloid receptors TRPV1. The non-psychoactive compound, cannabidiol, is the only component present at a high level in the extract able to bind to this receptor: thus cannabidiol was the drug responsible for the antinociceptive behaviour observed. In addition, the results showed that after chronic oral treatment with cannabis extract the hepatic total content of cytochrome P450 was strongly inhibited as well as the intestinal P-glycoprotein activity. It is suggested that the inhibition of hepatic metabolism determined an increased bioavailability of cannabidiol resulting in a greater effect. However, in the light of the well known antioxidant and antiinflammatory properties of terpenes and flavonoids which could significantly contribute to the therapeutic effects, it cannot be excluded that the synergism observed might be achieved also in the absence of the cytochrome P450 inhibition.”

http://www.ncbi.nlm.nih.gov/pubmed/18618522

Multiple sclerosis and extract of cannabis: results of the MUSEC trial.

Posted on by
1

“Multiple sclerosis (MS) is associated with chronic symptoms, including muscle stiffness, spasms, pain and insomnia. Here we report the results of the Multiple Sclerosis and Extract of Cannabis (MUSEC) study that aimed to substantiate the patient based findings of previous studies.”

“CONCLUSION:

The study met its primary objective to demonstrate the superiority of cannabis extract (CE) over placebo in the treatment of muscle stiffness in MS. This was supported by results for secondary efficacy variables. Adverse events in participants treated with CE were consistent with the known side effects of cannabinoids. No new safety concerns were observed.”

http://www.ncbi.nlm.nih.gov/pubmed/22791906

Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study.

Posted on by
Reply

“OBJECTIVE:

Cannabis may alleviate some symptoms associated with multiple sclerosis (MS). This study investigated the effect of an orally administered standardized Cannabis sativa plant extract in MS patients with poorly controlled spasticity.”

“CONCLUSION:

A standardized Cannabis sativa plant extract might lower spasm frequency and increase mobility with tolerable side effects in MS patients with persistent spasticity not responding to other drugs.”

http://www.ncbi.nlm.nih.gov/pubmed/15327040